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Whole-Genome Screening of
Newborns? The Constitutional
Boundaries of State Newborn
Screening Programs
Jaime S. King, PhD, JDa,b Monica E. Smith, JDb

abstract

State newborn screening (NBS) programs routinely screen nearly all of the 4 million
newborns in the United States each year for ~30 primary conditions and a number of
secondary conditions. NBS could be on the cusp of an unprecedented expansion as a result
of advances in whole-genome sequencing (WGS). As WGS becomes cheaper and easier
and as our knowledge and understanding of human genetics expand, the question of
whether WGS has a role to play in state NBS programs becomes increasingly relevant and
complex. As geneticists and state public health officials begin to contemplate the technical
and procedural details of whether WGS could benefit existing NBS programs, this is an
opportune time to revisit the legal framework of state NBS programs. In this article, we
examine the constitutional underpinnings of state-mandated NBS and explore the range
of current state statutes and regulations that govern the programs. We consider the legal
refinements that will be needed to keep state NBS programs within constitutional bounds,
focusing on 2 areas of concern: consent procedures and the criteria used to select new
conditions for NBS panels. We conclude by providing options for states to consider when
contemplating the use of WGS for NBS.
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Praised as one of the most successful
public health efforts of the 21st
century, state newborn screening
(NBS) programs routinely screen
nearly all of the 4 million newborns
in the United States each year for
hereditary and congenital diseases.
Originally established in 1963 to
screen for phenylketonuria (PKU),
the programs have expanded their
scope substantially over the last
50 years. State NBS programs
now analyze newborns’ blood for
~30 primary conditions and ≥25
secondary conditions detectable in
the process of confirming primary
conditions. Improvements in
genetic testing technology and in
our understanding of the etiology of
heritable disorders have contributed
significantly to this expansion.
NBS could be on the cusp of an
unprecedented expansion as a
result of advances in whole-genome
sequencing (WGS). As WGS becomes
cheaper and easier and as our
knowledge and understanding
of human genetics expands, the
question of whether WGS has a
role to play in state NBS programs
becomes increasingly relevant
and complex. To date, much of the
discussion surrounding the use of
WGS in NBS programs has focused
on feasibility, cost, reporting
requirements, and the appropriate
role of WGS in screening protocols.
Less attention has been paid to the
legal framework that would allow
state agencies to mandate testing for
a broader range of conditions.1–5

As geneticists and state public health
officials begin to contemplate the
technical and procedural details of
whether WGS could benefit existing
NBS programs, this is an opportune
time to revisit the legal framework
of state NBS programs. This article
examines their constitutional
underpinnings, explores the range of
current state statutes and regulations
that govern the programs, and
provides options for states to

consider when contemplating the use
of WGS for NBS.

Constitutional Foundations of
State NBS Programs
The state power to conduct public
health programs, such as NBS,
derives from 2 sources. First,
under the Constitution, the Tenth
Amendment reserves for the states
the “police power.” This power allows
states to implement programs to
protect “the health, safety, morals
and general welfare.”6 Second, a longstanding common law doctrine called
parens patriae permits states to make
decisions for the health and wellbeing of citizens who cannot speak
on their own behalf. This power is
often used to protect children and
the mentally incapacitated.7 Statemandated NBS involves both health
and children, so the police power
and the parens patriae power work
in combination to justify the state’s
ability to require screening.8

These 2 powers are not absolute,
however. Any attempt by the
government to mandate a medical
procedure must be weighed against
the individual’s constitutionally
protected interests in personal
autonomy and bodily integrity.
The Supreme Court has repeatedly
acknowledged that the Fourteenth
Amendment protects an adult
individual’s right to refuse unwanted
medical interventions. The
government can infringe on this
fundamental right only if it has a
compelling interest.9,10 Furthermore,
the Fourteenth Amendment protects
parents’ fundamental right to make
decisions about their minor child’s
welfare,11–13 including consenting to
their medical treatment.
If a parent objects to state-imposed
NBS, both the parent and the state
would have strong constitutionally
protected interests to support their
claim. In a conflict, a court would
have to balance these opposing
interests to decide whether the state

can mandate screening over parents’
objections. The parents could argue
that the Fourteenth Amendment
protects their right to refuse NBS
on behalf of their child, based on
the child’s right to bodily integrity
and their right to make decisions on
behalf of their child. But, “parents’
decision making for children does
not have the same constitutional
authority and protection against state
intervention as does a competent
adult’s personal health care decision
making.”8 The Supreme Court
has repeatedly held that the state
authority to regulate children’s lives
far exceeds its authority to regulate
the lives of adults. Furthermore, the
state’s police and parens patriae
powers give the state substantial
authority in matters relating to the
health and well-being of children.
Indeed, parental discretion is not
unlimited, especially when it is
used in ways that may endanger the
child.8,14 Typically, states have been
granted the opportunity to intervene
when the parents’ decisions put the
child at substantial risk of serious
harm or illness.15 As a result, states
have the ability to mandate NBS over
parent objection only in instances
where the screening will protect the
child from serious harm.16–18
Although the constitutional
requirements to mandate screening
have not shifted significantly since
NBS programs began, the factors
deemed relevant to screening and the
entities assessing which conditions
should be included in state NBS
programs have evolved substantially.
NBS programs initially targeted a
small set of genetic and metabolic
conditions for which failure to make
a timely diagnosis was associated
with a high probability of serious,
preventable harm to the child. In
such cases, the balance of state
and individual interests weighed
heavily in favor of permitting
states to require screening for all
newborns. Furthermore, treatment
was available to cure or stop the
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progression of the disease for each of
the initially selected severe childhood
disorders. PKU is a classic example of
a condition that justifies screening: It
is not clinically detectable until it has
caused irreversible harm, including
severe mental retardation; treatment
is simple (dietary management) and
can prevent or mitigate symptoms;
and the test is reliable, inexpensive,
and minimally invasive and can be
conducted early.19,20 The conditions
screened for in the early years of NBS
all shared these characteristics.

In the last 50 years, state NBS
programs have grown substantially,
both in the number of conditions
screened for and their characteristics.
A variety of forces drove this
expansion. First, the development of
tandem mass spectrometry allowed
laboratories to simultaneously target
several conditions, affordably and
efficiently, by using the same dried
blood spot used to test for PKU.
Second, organizations such as Easter
Seals and disease-specific patient
advocacy groups, such as Hunter’s
Hope Foundation, which advocated
for Krabbe screening in New York,
convinced state legislatures to
mandate screening for specific
conditions. Finally, the biggest single
expansion in state screening panels
came with the 2005 publication of
a report by the American College
of Medical Genetics and Genomics
(ACMG) recommending a uniform
screening panel.21 Ultimately adopted
by the secretary of health and human
services as a national standard for
state programs, the recommended
uniform screening panel (RUSP)
originally consisted of 29 primary
targets and 25 secondary conditions
likely to be discovered during
diagnostic confirmation of core test
results.
In selecting the primary targets, the
ACMG committee evaluated each
of 84 candidate disorders against
criteria pertaining to characteristics
of the condition, the screening test
for the condition, and available
S10

treatments. The scoring system
favored conditions that were not
likely to be detected clinically,
for which early intervention was
necessary to avoid serious harm, and
that were inexpensive and simple to
screen for, among other criteria.21
The scoring system worked to
justify screening for each condition
on the panel based on the potential
benefit to a child who received a
positive diagnosis. However, the
committee also strongly weighted
the ability to screen for a condition
via multiplex technology (ie, tandem
mass spectrometry). The inclusion
of multiplex capability in the initial
selection criteria set an undesirable
precedent for future evaluation
because it is not related to the child’s
benefit or the state interests that
support use of the police or parens
patriae powers.22 Technological
feasibility and cost-effectiveness
should be considered only after
sufficient patient benefit has been
established.

In 2008, the Newborn Screening
Saves Lives Act transferred
governance of the RUSP to the
Advisory Committee on Heritable
Diseases in Newborns and Children,23
and since that time the committee
has recommended inclusion of
only 4 additional conditions.24 The
committee recently augmented its
criteria to take account of states’
readiness to implement new
tests. Under the new criteria, the
committee first weighs the net
benefits of screening by analyzing the
importance of the health outcomes
to the population affected, the
estimated health benefits that could
result from testing, the possible
harms associated with testing for
the condition, and the efficacy and
effectiveness of testing and follow-up
as compared with usual clinical
practice.25 Only after the committee
has determined that screening for a
particular condition will provide high
or moderate certainty of significant
benefit for newborns will feasibility

and state readiness factor into a
decision to recommend a condition to
the RUSP. As a result, the committee’s
new decision matrix appropriately
addresses the constitutionally
relevant factors before any
consideration of implementation.
Although the committee recommends
conditions for inclusion in the RUSP
from a national perspective, decisions
about what conditions are screened
for and NBS implementation occur
entirely at the state level.

State Implementation of NBS
Programs
Laws governing NBS vary widely
from state to state in several areas
that will prove important especially
in the context of WGS. First, states
differ significantly in terms of their
requirements for informed consent,
the opportunity for parents to
decline screening, and available
exemptions (Table 1). Although all
states allow medical exceptions to
screening, little consensus exists
on other exemptions. In 3 states,
screening is mandatory, and the law
does not permit parents to opt out
for personal or religious reasons. In
30 states, parents may opt out only
on the basis of religion. Among states
that permit only religious objections,
the degree of proof parents must
provide to validate their religious
beliefs ranges from a sworn affidavit
to a simple signature on a form.
Some states require that parents be
practicing members of an established
church whose tenets forbid NBS.
Fifteen states honor “personal” or
philosophical objections in addition
to religious objections. Several
states, such as Arizona, California,
and Delaware, make NBS an explicit
exception to state laws generally
requiring informed consent of
patients or their parents for all
medical procedures. Only 2 states,
Maryland and Wyoming, expressly
require the parents’ informed
consent to conduct screening. Overall,
the state laws reflect a general
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consensus that the conditions tested
for in the existing NBS programs do
not require parental consent.

Furthermore, states do not require
the public health agencies to provide
parents with much information
about NBS. Although most states
have laws requiring NBS programs
to provide some information to
parents, few laws specify the
information requirements in any
depth. A handful of states require
that parents receive information
before the specimen is taken. Among
states that require information to
be given beforehand, some also
require programs to inform parents
of their right to object, or at least give
them a reasonable opportunity to
object, whereas others have no such
requirement.

Beyond informed consent, the
criteria states use for adding new
conditions and tests to screening
programs are highly relevant to the
potential integration of WGS into
NBS. A random sample of 24 states
reveals wide variation (Table 2).
Some states provide no criteria at
all in their laws and regulations.
Among states that do, no one set
of criteria appears repeatedly.
State laws often require that new
conditions be severe or serious and
treatable. They sometimes require
a cost–benefit analysis. A few states
mandate conformance with a uniform
panel such as the RUSP or another
set of recommendations from a
professional body.
As for the screening tests, states
may require that proposed tests
be reliable, accurate, efficient, or
consistent with accepted medical
practices. A few states require new
tests to be pilot-tested or already
implemented in another jurisdiction.
However, several states have no
criteria in law pertaining to new test
technologies.

Also striking is the absence of certain
criteria that are especially important

TABLE 1 State Laws Governing Consent for NBS
Consent Policies
No exemption for religion or
personal belief
Exemption for religion only

Must be members of
established church that
forbids NBS
Exemption for religion or for
personal or philosophical belief
Informed consent required before
screening
Must inform parent of right to
object
Must give parent reasonable
opportunity to object

Number of
States

States

3

AZ, NE, WV

30

9

AL, CA, CO, CT, DE, GA, HI, ID, IL, IN, KS, KY, MA, ME, MO,
MS, NJ, NY, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA,
WI, UT
CO, DE, ID, KY, NY, OR, TN, TX, UT

15

AK, AR, FL, IA, LA, MI, MN, MT, NC, ND, NH, NM, NV, SD, VT

2

MD, WY

3

MD, MN, WA

4

MD, MN, NJ, WI

This study examined statutes and regulations in each of the states. This chart does not reflect NBS program practices
that deviate from state law. Additional research is needed to determine the extent to which laws reflect current practice.

TABLE 2 Examples of Criteria in State Law for Inclusion of Condition in NBS Panel
Criterion

States

No criteria provided in law
Condition must be severe or serious
Treatable, preventable, or ameliorable
Cost–benefit analysis required
Conformity with uniform panel or recommendations of a
professional body
Test must be reliable
Test must be accurate
Test method must be efficient
Test must be consistent with accepted medical practices
Pilot testing or use in another jurisdiction required before full
implementation
No criteria in law for new test or technology

AR, NE
CA, CO, DE, GA, MA, MD, ME
CA, CO, GA, ID, KS, MA, ME
AZ, CO, MD, ME
FL, GA, IA, KS, KY
AL, AR, CO, CT, MA
AL, CA
AR, CO, IL
AK, CA, CO, FL, KS, MA
CO, IL
AZ, CT, DE, IA, ID, WA

The 24 states sampled are AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, NE, TN, and WA. This
study examined statutes and regulations in each of the states. This chart does not reflect NBS program practices that
deviate from state law. Additional research is needed to determine the extent to which laws reflect current practice.

in the arena of NBS, criteria that
relate to the constitutional and
ethical permissibility of screening
newborns without consent. Rarely
do state laws expressly require that
a new condition be one that is not
detectable in clinical practice, or
that has an early onset, or that needs
treatment during the asymptomatic
or newborn phase. Instead, state
legislatures often mandate a specific
panel of conditions and delegate to
a public agency the power to expand
the panel, with little or no guidance
as to disease characteristics.

A final area of concern is the absence
of special criteria or reporting

requirements for secondary findings.
Of the states we sampled, only 1,
Massachusetts, made a distinction in
law between primary and secondary
conditions. This distinction takes on
special significance in the context of
WGS. With current test methods, for
the most part secondary conditions
are true incidental findings; the state
laboratory reports a result, such
as an elevated level of a particular
analyte, to the pediatrician of record,
and a specialist then conducts
confirmatory testing and diagnosis,
which sometimes reveals a condition
other than the primary target. These
secondary conditions are medically
actionable, and there is little question
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that families would want to know
about them. However, WGS can
produce far more potential incidental
findings, requiring more discernment
on the part of states as to what
conditions should be targeted and
reported.1
Current state laws perhaps provide
adequate protections for the range
of conditions and test methods
used in NBS today. In the future,
however, if WGS is implemented
in NBS programs, states will need
protocols for determining when
parental consent is required and far
more robust criteria for choosing
appropriate screening targets
from among the myriad conditions
detectable by WGS.

The Implications of WGS for NBS
Currently, WGS is significantly more
expensive and time-consuming
than present NBS methods. At some
point in the future, as genetic testing
becomes cheaper and faster, it may
become more efficient and costeffective than current methods. If
that happens, WGS could be used
to provide new parents with an
expansive profile of their child’s
genetic characteristics and risks.
State NBS programs considering
adopting WGS must be cognizant of
the constitutional boundaries of their
authority to test newborns without
parental consent.
With the promise of WGS comes
an ever-growing tension between
a state’s ability to provide parents
with potentially useful information
soon after birth and its ability to
mandate such screening. Along with
immediately actionable results, WGS
can find conditions that are not well
understood, severe in prognosis,
highly penetrant, and treatable
in childhood. The state’s interest
in screening for such conditions
is weak and unlikely to outweigh
the strongly protected rights of
parents to make decisions for their
children and to protect their bodily
S12

integrity. Conducting mandatory
screening, without informed consent,
for numerous conditions that are
insufficient to justify the state’s
intrusion on patient autonomy
and parental rights will place state
programs in untenable legal and
ethical territory.

The constitution requires states to
either make tests voluntary or justify
mandating them. To incorporate WGS
into mandatory NBS without running
afoul of the constitution, states must
be able to justify the screening in
terms of the benefits to the child. The
benefits must outweigh the risks.
Even if WGS becomes cost-effective
enough to be used routinely, it will
still raise questions of accuracy and
relevance to the child’s health. The
risk of performing WGS on an infant
stems not from the blood draw
but from the discovery of genetic
information that is potentially
inaccurate, misleading, limited in its
utility, or simply undesired by the
parent. Gene sequencing may turn
out to be a more cost-effective way
to screen for the ~30 primary targets
on the current RUSP, but it will also
produce much more information.
State NBS programs that seek to use
WGS must decide what to do with any
information they obtain from WGS
that is not related to the primary
targets.

Options for Using WGS
States will need criteria for
determining which conditions can
legally be targeted as part of the
state’s primary panel and which
require some form of parental
consent. Furthermore, they will
need criteria to address variants
of unknown significance found
in target genes and variants of
known significance in nontarget
genes. Without obtaining informed
consent, states can use WGS to target
or confirm primary conditions.
However, consent is necessary
before any genes not associated with

primary conditions are analyzed.
Consent is also necessary before
any results are reported to families
other than conditions that are either
properly on a state’s primary panel
or directly implicated by analyzing
the gene for a primary condition.
For instance, when a targeted gene
sequence is probed for 1 mutation,
another mutation of potential
significance may be discovered.
State programs should establish
clear criteria for when a mutation
discovered in such a manner should
be reported.

The following are 3 general options
for the use of WGS in NBS programs:
1 without obtaining parental consent,
1 with an opt-in feature, and 1 that
would require full consent.

Option 1: Target or Confirm Only
Primary Conditions, Discard
Remaining Data

The first option states could pursue
is to use WGS, without informed
consent, to analyze the sequence
for anomalies related to primary
conditions on the screening panel,
and then immediately discard
the remaining sequence without
analysis. States could use WGS as a
first-tier or sole means of screening
for primary conditions provided
that it is a valid means of testing for
those conditions. States could also
use WGS as a second-tier test to
confirm presumptive positive results
obtained with other technologies. In
this situation, public health agencies
can screen without obtaining
parental consent as long as the
condition meets the legal criteria
for being targeted by a screening
program, and the laboratory analyzes
only the appropriate genes and
reports only the relevant results,
ignoring and discarding all other
data not uncovered by this process.
Bypassing informed consent in this
case should not breach constitutional
protections because the state’s
intrusion on the child’s autonomy
and the parent’s right to control the
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child’s health care is justified by the
nature of the primary conditions.

The second-tier use of genetic
sequencing has a parallel in state
programs today. The California
Newborn Screening Program screens
for cystic fibrosis via a mutation
panel of 40 known disease-causing
mutations. Cystic fibrosis is a
recessive disorder, which requires 2
mutations for the disease phenotype
to occur. When a newborn has ≥1
known disease-causing mutations,
the entire gene is sequenced,
which sometimes reveals variants
of unknown significance that can
lead to a referral for additional
evaluation. In this manner, California
uses DNA testing to identify second
mutations and confirm a positive
result before reporting results to the
family. Although California does not
sequence the whole-genome as part
of this protocol, it could do so legally
without obtaining consent provided
that it does not analyze irrelevant
genes and does not keep extraneous
data without consent.
Of course, this option makes sense
only if the cost and efficiency of
WGS improve enough to place it
on par with the cost of sequencing
individual genes. Even then, to many
doctors, parents, and policymakers it
may seem like a waste of resources
to sequence an entire genome only
to look at a small portion of it and
discard the rest. If WGS does become
a feasible technology for NBS, some
families will want information about
a wide range of conditions beyond
primary targets.

Option 2: Target Only Primary
Conditions and Give Parents the
Option to Receive the Full Genomic
Data in Raw Form

Instead of discarding the bulk of a
newborn’s sequenced genomic data,
as was proposed in option 1, the
state could also use WGS as a first- or
second-tier screen and grant parents
the ability to receive their child’s
raw sequence data. For parents who

do not want a copy of their child’s
sequence, the state should screen
for primary conditions, as it does
now, and then discard the sequence.
However, for parents who want to
know about additional variants or
have their child’s sequenced genome
transferred to their medical record
for future use, states could enable
parents to request the data. Providing
the raw sequence data, in the absence
of analysis, would necessarily require
the parents to seek the services of
a provider who could analyze and
interpret it, thereby minimizing the
risk of revealing unwanted genomic
information to the parents or child
without their express consent. If NBS
programs integrate WGS, consent for
raw data may be the most plausible
option.
Ideally, parents should be informed
of the opportunity to obtain the raw
sequence data from the state or have
it transferred to their pediatrician
as a standard part of prenatal care.
In preparing expectant mothers for
labor and delivery, obstetricians
often include a discussion about
hospital protocols and what to expect
throughout the process. As part of
that conversation, the obstetrician
or someone from his or her office
could provide pregnant women with
information from the state about the
NBS program and the opportunity
to choose to receive a copy of the
sequenced, but largely unanalyzed,
genomic data. States may want to
give parents a time line to request
the data before discarding it, perhaps
for up to 1 year. State programs
that choose to offer genomic data to
parents should consider including
information on genetic counseling
resources, key factors to consider in
deciding whether to retain the data,
and the procedures and deadlines
for requesting the data. States could
also create or recommend decision
aids to assist parents in weighing
their options.26 For parents who do
not receive this information during
prenatal care, hospitals could provide

such information before discharge,
or pediatricians could provide it
during the first year of pediatric care.
This option retains parents’ ability
to learn about their child’s genome
on their own terms and avoids
unnecessarily discarding a completed
WGS.

Option 3: Obtain Informed Consent
and Offer Parents Both the Genomic
Sequence and Analysis

Alternatively, some states
contemplating the use of WGS
in NBS may decide to integrate
informed consent into the program,
abandoning mandatory screening
entirely or requiring screening
only for primary conditions while
requesting consent to report all other
results. This approach acknowledges
that many parents will want access
to and control of their children’s
genomic data and that states may
want to ensure the quality of analysis
and interpretation provided to
parents from its data.

However, obtaining a fully informed
consent from parents for WGS
analysis will prove challenging.
Voluminous information about WGS
and the targeted conditions would
have to be condensed into easily
comprehensible and digestible
materials. Berg, Khoury, and Evans’s5
proposal to streamline informed
consent and genetic counseling by
classifying genetic conditions into
“predetermined clinically relevant
bins” could be adapted for use in
NBS. Researchers at the University of
North Carolina are already working
to classify conditions according to
characteristics relevant to consent,
resulting in such groupings as severe
early childhood disorders, late onset
disorders, disorders with moderate
mental or physical symptoms, and
predispositions to certain diseases.27
The process of defining the bins for
NBS informed consent would benefit
from the expertise and cooperation
of professional societies, such as
ACMG, the National Society of Genetic
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Counselors, and the American
Academy of Pediatrics, as well as
input from patient organizations
regarding the most effective way of
informing parents of their choices.
Parents could receive standardized
information on these panels of
conditions, choose what genes
should be analyzed and reported,
and decide what to do with the
balance of raw data. Furthermore,
decision aids are being developed to
help inform parents during prenatal
counseling.28 Giving parents the
relevant information and a range of
options regarding genetic testing
will protect their parental autonomy,
child’s bodily integrity, and the
child’s individual rights and preserve
the constitutionality of the state
program.
Providing for consent can help
resolve more than just the
constitutional problems. Many
parents worry about retention and
use of their children’s genetic data
obtained through NBS. By educating
parents during the prenatal period
about the use of WGS in NBS and
giving them control over reporting,
retention, and use of the newborn
bloodspots, states can also retain the
trust of their citizens and avoid at
least some of the expected political
opposition.28

Any of the 3 options for incorporating
WGS into NBS would bolster the
program’s constitutionality. Option
1 would incorporate WGS but not
offer parents access to any findings
beyond conditions currently tested
for through NBS. Therefore, states
should use WGS in this way only
if it proves more cost-effective or
accurate than existing options.
Options 2 and 3 would offer parents
substantially more information
but would also require the state
to establish a consent process for
obtaining either the raw sequence
data or more specific findings.
Establishing such a process will
require substantial input from a
range of interested parties and
S14

experts. Although many of these
discussions are already under way,
much of the most challenging work
remains.

protect both the state’s interests and
the fundamental rights of all citizens
living in their state.

Conclusions

Research reported in this
publication was supported by the
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development of the National
Institutes of Health under award
U19HD077627. The authors thank
Bob Currier, Barbara Koenig, Robert
Nussbaum, Lois Weithorn, and Flavia
Chen for their comments on earlier
versions of this article.

In the future, as improvements in
cost and efficiency make WGS more
suitable for NBS, many families will
no doubt want to take advantage of
the rich information that WGS can
provide. But integrating WGS into
NBS programs raises substantial
constitutional and statutory concerns
that states must address. Depending
on how it is used, WGS can generate
numerous findings, only a small
portion of which will be sufficiently
important to justify mandatory
testing and reporting. For any state
choosing to incorporate WGS into its
NBS program, transparency both in
how it intends to use WGS and what
it intends to do with the resulting
sequence will be essential. State
legislatures must set requirements
for informed consent procedures
that allow parents to meaningfully
object or consent to DNA analysis
and reporting of results. Given the
dramatic number of incidental
findings that could be revealed by
WGS, it is crucial that states carefully
distinguish between conditions
that they can and cannot report on
without parental consent. States must
establish meaningful procedures
to obtain informed consent from
parents before revealing information
beyond the primary conditions
targeted by the NBS program.
Without such protections, patients
are at risk for experiencing harms
that can result from receiving
medical knowledge without sufficient
context or support. Whether WGS
becomes part of NBS, states need to
clearly define and enforce criteria for
determining which conditions will
be targeted as part of the state NBS
programs. State policymakers have a
large role to play in the future of NBS,
which will require them to carefully
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